ADVANCED BREAST CANCER

This phase 2 study tests whether adding the experimental drug ipatasertib to standard hormone therapy and a targeted drug can help people with a specific type of advanced breast cancer (ER+/HER2-) live longer without their cancer growing. The study includes 57 participants whose …

This phase 3 study compares a new oral drug, ARV-471, to the standard treatment fulvestrant in about 624 adults with advanced ER+/HER2- breast cancer that worsened after prior hormone therapy. The main goal is to see if ARV-471 delays cancer growth better than fulvestrant. Partic…

This study tests a combination of two drugs (sacituzumab govitecan and bevacizumab) for people with metastatic triple-negative breast cancer that has already been treated. The goal is to see if the combo can shrink tumors or slow the disease. About 60 adults will take part across…

This study tests a new drug (MEN1611) combined with chemotherapy (eribulin) in people with advanced breast cancer that has specific genetic changes (PIK3CA/PTEN). The goal is to see if the combination can shrink tumors or stop them from growing. The trial includes 14 adults whose…

This study tests a new combination of drugs (trastuzumab, alpelisib, and possibly fulvestrant) against standard chemotherapy for people with a specific genetic mutation (PIK3CA) in HER2-positive advanced breast cancer. The goal is to see if the new combo can delay cancer growth b…

This study tests a combination of two drugs, alpelisib and fulvestrant, in Japanese men and postmenopausal women with a certain type of advanced breast cancer (HR+, HER2-) that has a PIK3CA gene change and has stopped responding to hormone therapy. The goal is to see if the combi…

This study tests a new combination of two drugs (Debio 0123 and sacituzumab govitecan) in people with advanced breast cancer that has not responded to prior treatments. The goal is to find a safe dose and see if the combination can shrink tumors. The study includes two types of b…

This study is for people with advanced HER2+ breast cancer whose cancer has spread to the brain but is stable elsewhere. Participants will continue their current treatment and add the drug tucatinib to see if it can delay or prevent new brain tumors. The goal is to improve contro…

This early-phase trial tests a drug called RYZ101 in people with a specific type of advanced breast cancer (ER+, HER2-) that has not responded to other treatments. The drug delivers radiation directly to cancer cells that have a certain marker (SSTR). The goal is to see if it is …

This study tests whether a specially trained Patient Support Coordinator (PSC) can help women with advanced or high-risk breast cancer feel heard and understood. The PSC provides emotional support and helps patients share their values and priorities with their medical team. The s…

This study looks at why the drug Palbociclib stops working in some people with advanced breast cancer. Researchers will collect blood and breath samples from 25 women over time to track changes in their cancer. The goal is to find patterns that signal when the drug is losing its …

This study looks at medical records from over 6,000 people with advanced breast cancer to see if researchers can get the same results as a past clinical trial (PALOMA-2) using only real-world data. The goal is to learn when and how to trust real-world data for future research. Pa…